Long-term temozolomide treatment induces marked amino metabolism modifications and an increase in TMZ sensitivity in Hs683 oligodendroglioma cells

Neoplasia

Volumn 12, Issue 1, 2010, Pages 69-79

  Lamoral Theys, Delphine ^a   Le Mercier, Marie ^a   Le Calvé, Benjamin ^a   Rynkowski, Michal A ^b   Bruyère, Céline ^a   Decaestecker, Christine ^a   Haibe Kains, Benjamin ^a,c   Bontempi, Gianluca ^a   Dubois, Jacques ^a   Lefranc, Florence ^a,b   Kiss, Robert ^a  

^a UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

^b ERASME HOSPITAL   (Belgium)

^c JULES BORDET INSTITUTE   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE P38; TEMOZOLOMIDE;

AMINO ACID METABOLISM; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CELL INVASION; CONTROLLED STUDY; DORMANCY; DRUG SENSITIVITY; GENOME ANALYSIS; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; LONG TERM CARE; MITOSIS RATE; MOUSE; NONHUMAN; OLIGODENDROGLIOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEOMICS; XENOGRAFT;

EID: 73949130687     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.91360     Document Type: Article

References (53)

1. Louis DN (2006). Molecular pathology of malignant gliomas. Annu Rev Pathol 1, 97-117.
2. Louis DN, Ohgaki H, Wiestler OD, and Cavenee WK (2007). WHO Classification of Tumours of the Central Nervous System. Lyon, France: International Agency for Research on Cancer (IARC).
3. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, et al. (2005). Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352, 987-996.
4. Stupp R, Hegi ME, Gilbert MR, and Chakravarti A (2007). Chemoradiotherapy in malignant glioma: standard of care and future directions. J Clin Oncol 25, 4127-4136.
5. Abrey LE, Louis DN, Paleologos N, Lassman AB, Raizer JJ, Mason W, Finlay J, MacDonald DR, DeAngelis LM, and Cairncross JG (2007). Survey of treatment recommendations for anaplastic oligodendroglioma. Neuro Oncol 9, 314-318. [6] Mikkelsen T, Doyle T, Anderson J, Margolis J, Paleologos N, Gutierrez J, Croteau D, Hasselbach L, Avedissian R, and Schultz L (2009). Temozolomide single-agent chemotherapy for newly diagnosed anaplastic oligodendroglioma. J Neurooncol 92, 57-63.
6. Bromberg JE and van den Bent MJ (2009).Oligodendrogliomas: molecular biology and treatment. Oncologist 14, 155-163.
7. Marchesi F, Turriziani M, Tortorelli G, Avvisati G, Torino F, and De Vecchis L (2007). Triazene compounds: mechanism of action and related DNA repair systems. Pharmacol Res 56, 275-287.
8. 6-methylguanine. Oncogene 26, 186-197.
9. Takagi Y, Hidaka M, Sanada M, Yoshida H, and Sekiguchi M (2008). Different initial steps of apoptosis induced by two types of antineoplastic drugs. Biochem Pharmacol 76, 303-311.
10. Mathieu V, De Neve N, LeMercier M, Dewelle J, Gaussin JF, Dehoux M, Kiss R, and Lefranc F (2008). Combining bevacizumab with temozolomide increases the antitumor efficacy of temozolomide in a human glioblastoma orthotopic xenograft model. Neoplasia 10, 1383-1392.
11. Kim JT, Kim JS, Ko KW, Kong DS, Kang CM, Kim MH, Son MJ, Song HS, Shin HJ, Lee DS, et al. (2006). Metronomic treatment of temozolomide inhibits tumor cell growth through reduction of angiogenesis and augmentation of apoptosis in orthotopic models of gliomas. Oncol Rep 16, 33-39.
12. Hegi ME, Diserens AC, Godard S, Dietrich PY, Regli L, Ostermann S, Otten P, Van Melle G, de Tribolet N, and Stupp R (2004). Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide. Clin Cancer Res 10, 1871-1874.
13. Wick W, Platten M, and Weller M (2009). New (alternative) temozolomide regimens for the treatment of glioma. Neuro Oncol 11, 69-79.
14. Kanzawa T, Germano IM, Komata T, Ito H, Kondo Y, and Kondo S (2004). Role of autophagy in temozolomide-induced cytotoxicity for malignant glioma cells. Cell Death Differ 11, 448-457.
15. Katayama M, Kawaguchi T, Berger MS, and Pieper RO (2007). DNA damaging agent-induced autophagy produces a cytoprotective adenosine triphosphate surge in malignant glioma cells. Cell Death Differ 14, 548-558.
16. Kislin KL, McDonough WS, Eschbacher JM, Armstrong BA, and Berens ME (2009). NHERF-1: modulator of glioblastoma cell migration and invasion. Neoplasia 11, 377-387.
17. Branle F, Lefranc F, Camby I, Jeuken J, Geurts-Moespot A, Sprenger S, Sweep F, Kiss R, and Salmon I (2002). Evaluation of the efficiency of chemotherapy in in vivo orthotopic models of human glioma cells with and without 1p19q deletions and in C6 rat orthotopic allografts serving for the evaluation of surgery combined with chemotherapy. Cancer 95, 641-655.
18. Le Mercier M, Lefranc F, Mijatovic T, Debeir O, Haibe-Kains B, Bontempi G, Decaestecker C, Kiss R, and Mathieu V (2008). Evidence of galectin-1 involvement in glioma chemoresistance. Toxicol Appl Pharmacol 229, 172-183.
19. LeMercier M, Mathieu V, Haibe-Kains B, Bontempi G, Mijatovic T, Decaestecker C, Kiss R, and Lefranc F (2008). Knocking down galectin 1 in human hs683 glioblastoma cells impairs both angiogenesis and endoplasmic reticulum stress responses. J Neuropathol Exp Neurol 67, 456-469.
20. Belot N, Rorive S, Doyen I, Lefranc F, Bruyneel E, Dedecker R, Micik S, Brotchi J, Decaestecker C, Salmon I, et al. (2001).Molecular characterization of cell substratum attachments in human glial tumors relates to prognostic features. Glia 36, 375-390.
21. Ikota H, Kinjo S, Yokoo H, and Nakazato Y (2006). Systematic immunohistochemical profiling of 378 brain tumors with 37 antibodies using tissue microarray technology. Acta Neuropathol 111, 475-482.
22. Hubstenberger A, Labourdette G, Baudier J, and Rousseau D (2008). ATAD 3A and ATAD 3B are distal 1p-located genes differentially expressed in human glioma cell lines and present in vitro anti-oncogenic and chemoresistant properties. Exp Cell Res 314, 2870-2883.
23. Sivasankaran B, Degen M, Ghaffari A, Hegi ME, Hamou MF, Ionescu MC, Zweifel C, Tolnay M, Wasner M, Mergenthaler S, et al. (2009). Tenascin-C is a novel RBPJκ-induced target gene for Notch signaling in gliomas. Cancer Res 69, 458-465.
24. Boulay JL, Miserez AR, Zweifel C, Sivasankaran B, Kana V, Ghaffari A, Luyken C, Sabel M, Zerrouqi A, Wasner M, et al. (2007). Loss of NOTCH2 positively predicts survival in subgroups of human glial brain tumors. PLoS ONE 2, e576.
25. LeMercier M, Fortin S, Mathieu V, Roland I, Spiegl-Kreinecker S, Haibe-Kains B, Bontempi G, Decaestecker C, Berger W, Lefranc F, et al. (2009). Galectin-1 proangiogenic and promigratory effects in the Hs683 oligodendroglioma model are partly mediated through the control of BEX2 expression. Neoplasia 11, 485-496.
26. Decaestecker C, Camby I, Gordower L, De Witte O, Cras P, Martin JJ, Pasteels JL, Van Ham P, Brotchi J, Kiss R, et al. (1998). Characterization of astroglial versus oligodendroglial phenotypes in glioblastomas by means of quantitative morphonuclear variables generated by computer-assisted microscopy. J Neuropathol Exp Neurol 57, 791-802.
27. He J, Mokhtari K, Sanson M, Marie Y, Kujas M, Huguet S, Leuraud P, Capelle L, Delattre JY, Poirier J, et al. (2001). Glioblastomas with an oligodendroglial component: a pathological and molecular study. J Neuropathol Exp Neurol 60, 863-871.
28. Fisher T, Galanti G, Lavie G, Jacob-Hirsch J, Kventsel I, Zeligson S, Winkler R, Simon AJ, Amariglio N, Rechavi G, et al. (2007). Mechanisms operative in the antitumor activity of temozolomide in glioblastoma multiforme. Cancer J 13, 335-344.
29. Dumont P, Ingrassia L, Rouzeau S, Ribaucour F, Thomas S, Roland I, Darro F, Lefranc F, and Kiss R (2007). The Amaryllidaceae isocarbostyril narciclasine induces apoptosis by activation of the death receptor and/or mitochondrial pathways in cancer cells but not in normal fibroblasts. Neoplasia 9, 766-776.
30. Mathieu V, Mijatovic T, van Damme M, and Kiss R (2005). Gastrin exerts pleiotropic effects on human melanoma cell biology. Neoplasia 7, 930-943.
31. Megalizzi V, Mathieu V, Mijatovic T, Gailly P, Debeir O, De Neve N, Van Damme M, Bontempi G, Haibe-Kains B, Decaestecker C, et al. (2007). 4-IBP, a sigma1 receptor agonist, decreases the migration of human cancer cells, including glioblastoma cells, in vitro and sensitizes them in vitro and in vivo to cytotoxic insults of proapoptotic and proautophagic drugs. Neoplasia 9, 358-369.
32. Mijatovic T, Mathieu V, Gaussin JF, DeNeve N, Ribaucour F, Van Quaquebeke E, Dumont P, Darro F, and Kiss R (2006). Cardenolide-induced lysosomal membrane permeabilization demonstrates therapeutic benefits in experimental human non-small cell lung cancers. Neoplasia 8, 402-412.
33. Beier D, Rohrl S, Pillai DR, Schwarz S, Kunz-Schughart LA, Leukel P, Proescholdt M, Brawanski A, Bogdahn U, Trampe-Kieslich A, et al. (2008). Temozolomide preferentially depletes cancer stem cells in glioblastoma. Cancer Res 68, 5706-5715.
34. Lee da Y and Gutmann DH (2007). Cancer stem cells and brain tumors: uprooting the bad seeds. Expert Rev Anticancer Ther 7, 1581-1590.
35. Sanai N, Alvarez-Buylla A, and Berger MS (2005). Neural stem cells and the origin of gliomas. N Engl J Med 353, 811-822.
36. Hosack DA, Dennis G Jr, Sherman BT, Lane HC, and Lempicki RA (2003). Identifying biological themes within lists of genes with EASE. Genome Biol 4, R70.
37. Vie N, Copois V, Bascoul-Mollevi C, Denis V, Bec N, Robert B, Fraslon C, Conseiller E, Molina F, Larroque C, et al. (2008). Overexpression of phosphoserine aminotransferase PSAT1 stimulates cell growth and increases chemoresistance of colon cancer cells. Mol Cancer 7, 14.
38. Zhou W, Feng X, Li H, Wang L, Zhu B, Zhang H, Yao K, and Ren C (2007). Functional evidence for a nasopharyngeal carcinoma-related gene BCAT1 located at 12p12. Oncol Res 16, 405-413.
39. Eden A and Benvenisty N (1999). Involvement of branched-chain amino acid aminotransferase (Bcat1/Eca39) in apoptosis. FEBS Lett 457, 255-261.
40. Lecca MR, Wagner U, Patrignani A, Berger EG, and Hennet T (2005). Genome-wide analysis of the unfolded protein response in fibroblasts from congenital disorders of glycosylation type-I patients. FASEB J 19, 240-242.
41. Harding HP, Zhang Y, Zeng H, Novoa I, Lu PD, Calfon M, Sadri N, Yun C, Popko B, Paules R, et al. (2003). An integrated stress response regulates amino acid metabolism and resistance to oxidative stress. Mol Cell 11, 619-633.
42. SAPK and ER-stress signaling: an adaptive advantage for metastatic cells? Cancer Biol Ther 5, 729-735.
43. Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, Ludwin SK, Allgeier A, Fisher B, Belanger K, et al. (2009). Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomized phase III: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10, 459-466.
44. Rebetz J, Tian D, Persson A, Widegren B, Salford LG, Englund E, Gisselsson D, and Fan X (2008). Glial progenitor-like phenotype in low-grade glioma and enhanced CD133-expression and neuronal lineage differentiation potential in high-grade glioma. PloS ONE 3, e1936.
45. + cancer stem cells in glioblastoma. Mol Cancer 5, 67.
46. Vander Heiden MG, Cantley LC, and Thompson CB (2009). Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 324, 1029-1033.
47. Sun X, Zhang N, Li K, Liu M, Zhi X, Jiang X, and Shou N (2003). Branched chain amino acid imbalance selectively inhibits the growth of gastric carcinoma cells in vitro. Nutr Res 23, 1279-1290.
48. Martens JW, Nimmrich I, Koenig T, Loop MP, Harbeck N, Model F, Kluth A, Bolt-de Vries J, Sieuwerts AM, Portengen H, et al. (2005). Association of DNA methylation of phosphoserine aminotransferase with response to endocrine therapy in patients with recurrent breast cancer. Cancer Res 65, 4101-4417.
49. Camby I, Belot N, Lefranc F, Sadeghi N, de Launoit Y, Kaltner H, Musette S, Darro F, Danguy A, Salmon I, et al. (2002). Galectin-1 modulates human glioblastoma cell migration into the brain through modifications to the actin cytoskeleton and levels of expression of small GTPases. J Neuropathol Exp Neurol 61, 585-596.
50. 1 in glioblastoma cells. Brain Pathol .
51. Bulavin DVand Fornace AJ Jr (2004). p38 MAP kinase's emerging role as a tumor suppressor. Adv Cancer Res 92, 95-118.
52. Aguirre-Ghiso JA, Estrada Y, Liu D, and Ossowski L (2003). ERK(MAPK) activity as a determinant of tumor growth and dormancy; regulation by p38(SAPK). Cancer Res 63, 1684-1695.
53. Udagawa T (2008). Tumor dormancy of primary and secondary cancers. APMIS 116, 615-628.